Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Virttu Biologics Ltd.

Harnessing the herpes virus to combat cancer

This article was originally published in Start Up

Executive Summary

Despite a long history of disappointments, many experts now agree that viral therapy of cancer could soon become a reality. Accumulating clinical evidence indicates that researchers have figured out how to modify and enhance viruses in ways that make them both safe and effective. For its part, Virttu Biologics Ltd. is developing a single-deletion variant of HSV it calls SEPREHVIR. Research carried out at Virttu, as well as at the University of Glasgow where the core technology was developed, shows that the mutated virus is taken up by and remains in tumor tissue, without infecting surrounding healthy tissue.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts